Welcome to our dedicated page for Intellia Therape news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therape stock.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage gene editing company whose news flow centers on the development of CRISPR-based therapies. Company announcements frequently highlight progress in its in vivo programs, including nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis and lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE). Investors following NTLA news can see updates on clinical trial data, regulatory interactions and platform developments that shape the company’s pipeline.
Recent Intellia press releases and SEC-furnished materials describe longer-term Phase 1 and Phase 1/2 data for nex-z and lonvo-z, pooled analyses of patient outcomes, and details from global Phase 3 trials such as MAGNITUDE, MAGNITUDE-2 and HAELO. News items also cover events such as temporary pauses in patient dosing, FDA clinical holds on Phase 3 nex-z trials, and subsequent company plans to work with regulators. These disclosures provide insight into both the potential and the risks associated with Intellia’s CRISPR-based candidates.
Beyond clinical results, NTLA news includes quarterly financial updates, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and investor presentations at major healthcare conferences. Together, these items give a view into Intellia’s operational progress, capital position and strategic priorities as it advances gene editing therapies for serious diseases like ATTR amyloidosis and HAE.
This news page aggregates Intellia’s latest press releases and related market-moving information in one place, allowing readers to review clinical milestones, regulatory developments and corporate updates linked to the NTLA stock.
Intellia Therapeutics (Nasdaq: NTLA) announced on March 6, 2026 that it granted inducement awards to six new employees under its 2024 Inducement Plan.
The awards were time-based restricted stock units totaling 16,500 shares, with one-third vesting annually over three years, granted March 1, 2026 and approved under Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (Nasdaq: NTLA) presented four posters at AAAAI 2026 on lonvoguran ziclumeran (lonvo-z; NTLA-2002) for hereditary angioedema (HAE). A pooled Phase 1/2 cohort (n=32) given a one-time 50 mg dose showed durable plasma kallikrein reductions and a mean monthly attack rate ≤0.2 through up to three years.
Key readouts: 96% mean reduction in HAE attacks versus baseline, 31/32 (97%) attack-free and LTP-free at data cutoff, and 86% of 28 patients with >6 months follow-up attack-free and LTP-free for >6 months. A patient survey (n=100) highlighted ongoing treatment burden.
Intellia Therapeutics (Nasdaq: NTLA) announced the FDA has lifted the clinical hold on the IND for the MAGNITUDE Phase 3 trial of nexiguran ziclumeran (nex-z) in ATTR-CM, allowing enrollment to resume with enhanced safety measures.
Holds were originally placed on October 29, 2025 after a patient experienced Grade 4 liver transaminase elevations and increased bilirubin. Mitigations include intensified liver monitoring, short-term steroid guidance, new exclusion criteria (including ejection fraction <25% and recent cardiovascular instability), and exclusion for certain liver abnormalities. MAGNITUDE plans ~1,200 patients (2:1 randomization, single 55 mg infusion); MAGNITUDE-2 enrolls ~60 ATTRv-PN patients (1:1).
Intellia Therapeutics (Nasdaq: NTLA) reported Q4 and full-year 2025 results and program updates. Key items: HAELO Phase 3 topline data expected mid-2026, planned BLA submission in second half of 2026 and potential U.S. launch in first half of 2027 for lonvo-z. MAGNITUDE-2 enrollment to resume with completion expected in H2 2026; MAGNITUDE (ATTR-CM) remains on FDA clinical hold. Cash, cash equivalents and marketable securities were $605.1M at year-end, expected to fund operations into H2 2027.
Intellia Therapeutics (Nasdaq: NTLA) announced management will participate in three investor conferences in early March 2026, including TD Cowen (March 3), Leerink Global Healthcare (March 9) and Barclays Global Healthcare (March 10). The March 3 and March 9 fireside chats will be webcast live.
Webcasts and replays will be available on the company's Events and Presentations page at intelliatx.com; replays will remain available for approximately 90 days after each event.
Intellia Therapeutics (Nasdaq: NTLA) will host a conference call on February 26, 2026 at 8:00 a.m. ET to discuss fourth-quarter and full-year 2025 financial results and business updates.
Investors may join via webcast or teleconference; a replay will be available for approximately 90 days on the company’s Events page.
Intellia Therapeutics (Nasdaq: NTLA) announced inducement equity awards granted on February 1, 2026 under its 2024 Inducement Plan.
The company awarded time-based restricted stock units totaling 30,600 shares to six new employees, vesting one-third annually over three years, subject to continued service. Awards were approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) said the FDA has lifted the clinical hold on the MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).
The company plans to resume patient enrollment and dosing, has aligned with FDA on certain study modifications including enhanced liver safety monitoring, and increased MAGNITUDE-2 target enrollment from ~50 to ~60 patients. Engagement with FDA remains ongoing for the related MAGNITUDE Phase 3 trial in transthyretin amyloidosis with cardiomyopathy (ATTR-CM); an update will follow after alignment on the path forward.
Intellia Therapeutics (NASDAQ:NTLA) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026 at 9:00 a.m. PT. A live webcast will be available on the company’s Events and Presentations page in the Investors & Media section at www.intelliatx.com. A replay of the webcast will be available on the website for approximately 30 days after the presentation.
Intellia Therapeutics (NASDAQ: NTLA) announced that on January 1, 2026 it awarded inducement grants to two new employees under its 2024 Inducement Plan.
The grants are time-based restricted stock units totaling 22,800 shares of common stock, with one-third vesting annually over three years and vesting subject to continued service. The 2024 Inducement Plan was adopted by the board in June 2024. The awards were approved by Intellia’s compensation committee as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).